Case Report: TPR-ALK fusion-positive inflammatory myofibroblastic tumour treated with sequential ALK inhibitors

BackgroundInflammatory myofibroblastic tumour (IMT) is a rare mesenchymal neoplasm, frequently driven by oncogenic kinase fusions, most commonly involving anaplastic lymphoma kinase (ALK). Standard cytotoxic therapies have limited efficacy in unresectable IMT. ALK inhibitors such as crizotinib are r...

Полное описание

Библиографические подробности

Главные авторы:	Fabiano Flauto, Filippo Vitale, Caterina De Luca, Rosa Maria Di Crescenzo, Francesco Petteruti, Annarita Peddio, Giuseppe Neola, Vincenzo Damiano
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2026-03-01
Серии:	Frontiers in Oncology
Предметы:	ALK-fusion case report inflammatory myofibroblastic tumour lorlatinib TPR-ALK
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1778283/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!